MX2019000582A - Forma cristalina de un intermediario de la dapagliflozina y metodo de preparacion del mismo. - Google Patents
Forma cristalina de un intermediario de la dapagliflozina y metodo de preparacion del mismo.Info
- Publication number
- MX2019000582A MX2019000582A MX2019000582A MX2019000582A MX2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A MX 2019000582 A MX2019000582 A MX 2019000582A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- crystal form
- method therefor
- dapagliflozin
- dapagliflozin intermediate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Se describen una forma cristalina de un intermediario de la dapagliflozina y un método de preparación del mismo y se describen, específicamente, una forma cristalina del intermediario de la dapagliflozina ( 2S, 3R,4S, 5S, 6R)-2-( 4- cloro- 3-( 4- etoxibencil) fenil)-2- etoxi- 6-( metilhidroxil)tetrahidro- 2H-piran- 3, 4, 5- triol y un método de preparación del mismo. Las ventajas del mismo radican en que un intermediario puede ser purificado altamente para obtener una muestra con una pureza de 99.3% o más, en donde el mismo tiene un alcance importante para mejorar la calidad de la dapagliflozina y el proceso de preparación es simple y adecuado para la producción industrial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610587582.7A CN107641139A (zh) | 2016-07-22 | 2016-07-22 | 达格列净中间体的晶型及其制备方法 |
| PCT/CN2017/093833 WO2018014866A1 (zh) | 2016-07-22 | 2017-07-21 | 达格列净中间体的晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000582A true MX2019000582A (es) | 2019-04-01 |
Family
ID=60992959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000582A MX2019000582A (es) | 2016-07-22 | 2017-07-21 | Forma cristalina de un intermediario de la dapagliflozina y metodo de preparacion del mismo. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10836786B2 (es) |
| EP (1) | EP3489250A4 (es) |
| JP (1) | JP2019521151A (es) |
| KR (1) | KR20190031485A (es) |
| CN (2) | CN107641139A (es) |
| BR (1) | BR112019000521A2 (es) |
| MX (1) | MX2019000582A (es) |
| WO (1) | WO2018014866A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020151672A1 (zh) * | 2019-01-23 | 2020-07-30 | 苏州科睿思制药有限公司 | 一种达格列净晶型及其制备方法和用途 |
| EP4114365A1 (en) | 2020-03-05 | 2023-01-11 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising sglt2 inhibitor |
| CN111748004A (zh) * | 2020-06-30 | 2020-10-09 | 药璞(上海)医药科技有限公司 | 一种高纯度达格列净中间体的晶型及其制备方法 |
| CN114539334A (zh) * | 2021-03-31 | 2022-05-27 | 浙江美诺华药物化学有限公司 | 一种达格列净中间体化合物晶型及其制备方法 |
| CN116813675B (zh) * | 2023-08-23 | 2023-11-24 | 北京远大九和药业有限公司 | 一种化合物晶型及其制备、组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295422A3 (de) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2013152476A1 (en) * | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Process for the preparation of benzylbenzene sglt2 inhibitors |
| US9193751B2 (en) * | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
| CN104109179A (zh) * | 2013-04-16 | 2014-10-22 | 杭州华东医药集团生物工程研究所有限公司 | 一类c-芳基葡萄糖苷衍生物、制备方法及其用途 |
| IN2014CH01141A (es) * | 2014-03-06 | 2015-09-11 | Msn Lab Private Ltd | |
| CN105481915A (zh) * | 2014-09-19 | 2016-04-13 | 北京万生药业有限责任公司 | 一种sglt-2抑制剂化合物的制备方法 |
-
2016
- 2016-07-22 CN CN201610587582.7A patent/CN107641139A/zh active Pending
-
2017
- 2017-07-21 CN CN201780033823.6A patent/CN109219611B/zh active Active
- 2017-07-21 BR BR112019000521-8A patent/BR112019000521A2/pt not_active IP Right Cessation
- 2017-07-21 WO PCT/CN2017/093833 patent/WO2018014866A1/zh unknown
- 2017-07-21 US US16/317,636 patent/US10836786B2/en active Active
- 2017-07-21 JP JP2019501701A patent/JP2019521151A/ja active Pending
- 2017-07-21 KR KR1020197001816A patent/KR20190031485A/ko not_active Application Discontinuation
- 2017-07-21 MX MX2019000582A patent/MX2019000582A/es unknown
- 2017-07-21 EP EP17830500.9A patent/EP3489250A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN107641139A (zh) | 2018-01-30 |
| WO2018014866A1 (zh) | 2018-01-25 |
| US10836786B2 (en) | 2020-11-17 |
| BR112019000521A2 (pt) | 2019-04-24 |
| KR20190031485A (ko) | 2019-03-26 |
| CN109219611A (zh) | 2019-01-15 |
| EP3489250A4 (en) | 2020-02-26 |
| CN109219611B (zh) | 2022-03-29 |
| JP2019521151A (ja) | 2019-07-25 |
| US20190284220A1 (en) | 2019-09-19 |
| EP3489250A1 (en) | 2019-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000582A (es) | Forma cristalina de un intermediario de la dapagliflozina y metodo de preparacion del mismo. | |
| AU2015327117A8 (en) | Tellurate joining glass having processing temperatures less than or equal to 420 °C | |
| MX2018006606A (es) | Metodo para producir d-psicosa de alta pureza. | |
| AU2018271755A1 (en) | Method for culturing natural killer cell, using transformed T cell | |
| WO2016196315A3 (en) | Cell culture methods and systems | |
| EA201891668A1 (ru) | Управление продуктом в процессах биологической конверсии | |
| MX2019009135A (es) | Ingenieria metabolica para la produccion microbiana de productos terpenoides. | |
| MX345378B (es) | Procedimiento para inocular levadura en zumo de frutas. | |
| CN107001236A8 (zh) | 一种1,5‑戊二胺的纯化方法及1,5‑戊二胺 | |
| MY184725A (en) | Process for the purification of biomass hydrolysate | |
| MY172080A (en) | Microorganisms having putrescine productivity and process for producing putrescine using the same | |
| MX2022000253A (es) | Proceso de fermentacion industrial para celulas microbianas mediante el uso de un precultivo de alimentacion por lotes. | |
| PH12020500328A1 (en) | Microorganism for producing a mycosporine-like amino acid and method for producing a mycosporine-like amino acid using the same | |
| MX2021012523A (es) | Método de purificación de toxina botulínica. | |
| MX2019011730A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| MX2021012296A (es) | Microorganismo que produce l-aminoacido y procedimiento de produccion de l-aminoacido mediante el uso del mismo. | |
| EP2735609A3 (en) | Method to Increase the Yield of Products in Plant Material | |
| MY185835A (en) | Novel variant of o-phosphoserine exporter and method of producing o-phosphoserine, cysteine, and its derivatives using the same | |
| MX2016002870A (es) | Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles. | |
| MX2021008301A (es) | Proceso de purificacion de ficocianinas. | |
| MX2017009714A (es) | Metodos para producir compuesto de pirazin carboxamida e intermediario sintetico del mismo. | |
| TW201612120A (en) | Method for cutting non-alkali plate glass, method for cutting display panel, method for producing non-alkali plate glass, and method for producing display panel | |
| MY194572A (en) | Self-sufficient process for the production of biomass hydrolysate with reduced salt content | |
| WO2019215753A3 (en) | Process for preparation of pure plecanatide | |
| DK201470284A (en) | Method for producing high purity crystalline carbamide |